长期服用主流降脂药,安全是第一道“坎”目前,国人血脂异常呈现“三低一高”的局面:低知晓率、低检测率、低达标率和高发病率。在我国血脂异常人群中,需降脂药物干预的心血管高危或极高危者占到了84%,而造成这一状况的原因与患者没有进行积极合理的药物治疗有关。他汀类降脂药的临床获益已为大量的循证医 Long-term use of mainstream lipid-lowering drugs, safety is the first “Kan ” At present, people with dyslipidemia “three low and one high ” situation: low awareness, low detection rate, low compliance rate and high morbidity. In our population with dyslipidemia, 84% of the patients with cardiovascular risk or extremely high risk of needing lipid-lowering drug intervention are related to the lack of positive and reasonable drug treatment in patients. The clinical benefit of statin lipid-lowering drugs has been extensive evidence-based medicine